Article Type
Case Report
Published
This case report presents initial experience with a patient affected by primary myelofibrosis, retreated with ruxolitinib after a 3-month suspension of
therapy due to clinical decision.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.